TORONTO, May 26, 2011 /CNW/ - Executives from more than 60 Canadian life sciences companies will
gather in Toronto next week at BioFinance 2011 to celebrate the
industry successes of the previous year and discuss the challenges and
opportunities looking forward.
BioFinance 2011 will be held on May 31 and June 1, 2011, at the St.
Andrew's Club & Conference Centre and will showcase presentations of the product and investment opportunities of these companies. Fourteen panels comprised of industry experts will explore financing and management
issues specific to the life sciences industry.
"There were many successes in the Canadian biotech industry worth
celebrating in 2011," said Mr. Michael Stinson, Executive Director of BioFinance Canada. "On the product side, for example, Theratechnologies Inc. completed
the lengthy and demanding process for the approval of their novel drug.
This was complemented by other companies obtaining approval of
specialty pharmaceutical products, medical devices and diagnostic
"Also encouraging is that funding of public development stage healthcare
companies has shown recent momentum," continued Mr. Stinson. "Equity
and convertible debt funding amounted to $259 million in Q4 2010, and
seven companies have completed financings of over $10 million so far in
Panels at BioFinance 2011 will discuss the numerous sources that
Canadian companies have successfully tapped to fund their product
development and commercialization efforts. Canadian institutional and
venture capital fund managers will provide their perspective on the
competition for small cap funding in Canada. The U.S. investment
community has been a source of funding for over two decades and will be
represented by investment bankers and venture capital fund managers.
Partnerships with large biotechnology and pharmaceutical companies will
continue as a major source of funding for the smaller companies.
"Success for the industry in 2011 and subsequent years will be defined
by clinical, regulatory and financing achievements, and by share price
performance of the companies," said Dr. Wayne Schnarr, Healthcare
Consultant for TMX Equicom. "If the industry is able to repeat the
clinical and regulatory success rate of 2010, it is expected that
financing and share price performance will follow."
BioFinance is the leading investor conference in Canada for the life sciences
industry. The two day event brings together key industry players and
companies interested in investment opportunities and issues affecting
the life sciences sector. Presenting companies span a range of
industries including: biologics, medical devices, drug delivery,
vaccines, diagnostics, ag-biotech, and research services. For more
information or to register for BioFinance 2011, please visit www.biofinance.ca.
SOURCE BioFinance Canada
For further information: